Results for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- 87 of 108 participants experienced an adverse reaction 24 hours post-vaccination, with the most common being fever, fatigue, headache, and muscle pain. 9 participants had severe fever (grade 3) with temperatures around 38·5°C. These reactions did not persist past 48 hours after injection. There were no significant differences in the incidences of adverse reactions among the dosage groups.
- Rapid antibody response to RBD was detected in all 3 dosage groups at day 14.
- IFNγ was detected from CD4+ and CD8+T cells at day 14 and day 28.
- The Ad5 vaccine was able to induce humoral and T-cell responses rapidly in most participants. T-cell responses peaked at 14 days, and antibodies at 28 days. Those with high pre-existing Ad5 had at least a four-fold increase in neutralizing antibody titer after 28 days. It also reduced the peak of the T-cell responses, especially for the low dosage group.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Results for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Discussion on Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial